$15.06
−$0.31−2.02%
Delayed · · marketstack
−$1.65−9.87%over 1M
No fundamentals are published for this symbol. That is normal for funds and for recently listed companies.
No comments yet
Set a username to join the discussion. It’s the only thing shown next to what you post, never your email address.
Comments are written by other users. Nothing here is investment advice and nothing is checked for accuracy.
Updated · the last close
What AAPG has filed with the SEC. This is not Ascentage Pharma Group International’s own investor relations site: these filings are the primary source that site publishes from.
AAPG is among the largest companies matching:
The assistant answers from what AAPG has actually filed: 3 annual reports filed with the SEC and 4 Form 4 filings from the last year. Every figure in a reply links to the filing it came from, so an answer can be checked rather than believed.
Press one and the answer appears right here on the page, from AAPG's filings and figures. One a day without an account; a free account has its own, and no card.
See how much of Ascentage Pharma Group International each of these investors holds, and every quarter they moved.
Ten seconds. No card. Nothing to cancel.
Be told the moment a AAPG insider trades
Put Ascentage Pharma Group International on a watchlist for a free alert, the bell and a daily email, when a Form 4 worth a row is filed, with vesting and automatic tax sales already struck out so what lands is a decision, not paperwork.
The full filing historyMeasure
Ask what growth the price is already betting on
Ascentage Pharma Group International's income statement, balance sheet and cash flow as filed, and the ratios computed from them, plus a reverse DCF that holds today's price fixed and solves for the growth it requires.
The reverse DCFMeasure
Watch the same stakes the professionals are watching
Every tracked position priced at the quarter it was filed and diffed against the one before it: how big a bet each one is, and by how much it changed.
Every position, sizedMeasure
Interrogate the filing, not the internet
Ask anything about Ascentage Pharma Group International's fundamentals. The assistant answers from its own filings and cites the figure, never a guess from the open web.
Free, no card, and it does not expire.
38 more events are on Measure
Free, no card, and it does not expire. See what the paid plans add
Revenue grew from $209.71M in FY2022 to $980.65M in FY2024, a compounded annual growth rate of 116.2%. Gross margin expanded to 97.0% in FY2024 from 89.5% in FY2022. Net margin improved significantly to -41.3% in FY2024 from -421.0% in FY2022, though the company remained unprofitable.
This is one section of Ascentage Pharma Group International’s Company Brief. The full memo also covers what the company does, where the cash goes, its risk factors, who owns it, and what today’s price implies.
Free, no card, and it does not expire. See what the paid plans add